| Osteoporosis
Tymlos vs Forteo
Side-by-side clinical, coverage, and cost comparison for osteoporosis.Deep comparison between: Tymlos vs Forteo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsForteo has a higher rate of injection site reactions vs Tymlos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Forteo but not Tymlos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tymlos
Forteo
At A Glance
SC injection
Once daily
PTH1R agonist
SC injection
Once daily
PTH analog
Indications
- Osteoporosis
- Osteoporosis
- Primary osteoporosis
- Osteoporosis steroid-induced
Dosing
Osteoporosis 80 mcg subcutaneously once daily into the periumbilical region of the abdomen; treatment duration not to exceed 2 years during a patient's lifetime.
Osteoporosis, Primary osteoporosis, Osteoporosis steroid-induced 20 mcg subcutaneously once daily into the thigh or abdominal region; use for more than 2 years during a patient's lifetime only if the patient remains at or has returned to high risk for fracture.
Contraindications
- History of systemic hypersensitivity to abaloparatide or any component of the product formulation
- Hypersensitivity to teriparatide or any of its excipients
Adverse Reactions
Most common (>=2%) Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, abdominal pain upper, vertigo, injection site redness, injection site edema, injection site pain, tachycardia
Serious Orthostatic hypotension, hypercalcemia, hypercalciuria and urolithiasis
Postmarketing Abdominal distension, abdominal pain, constipation, diarrhea, vomiting, decreased appetite, asthenia, lethargy, malaise, hot flush, insomnia, hypersensitivity and anaphylactic reactions, dyspnea, pruritus, rash, generalized pain, blood pressure increased, muscle spasms, injection site bruising and hemorrhage
Most common (>10%) Arthralgia, pain, nausea
Postmarketing Anaphylactic reactions, angioedema, urticaria, drug hypersensitivity, osteosarcoma, hyperuricemia, acute dyspnea, chest pain, muscle spasms of the leg or back, injection site reactions, oro-facial edema
Pharmacology
Abaloparatide is a PTHrP(1-34) analog that acts as an agonist at the PTH1 receptor (PTH1R), activating the cAMP signaling pathway and stimulating osteoblastic activity to promote new bone formation on trabecular and cortical bone surfaces.
Teriparatide is a recombinant human parathyroid hormone analog (PTH 1-34) that binds PTH cell-surface receptors and stimulates new bone formation by preferential stimulation of osteoblastic over osteoclastic activity on trabecular and cortical bone surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tymlos
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (12/12) · Qty limit (12/12)
Forteo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Tymlos
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (3/8)
Forteo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Tymlos
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Forteo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Neurofibromatosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Neurofibromatosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TymlosView full Tymlos profile
ForteoView full Forteo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.